Literature DB >> 23300235

All-cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study.

Marjolein P M Hensgens1, Abraham Goorhuis, Olaf M Dekkers, Birgit H B van Benthem, Ed J Kuijper.   

Abstract

BACKGROUND: Mortality among patients with Clostridium difficile infection (CDI) is high. Because of high age and multiple underlying diseases, CDI-related mortality is difficult to estimate. We estimated CDI-related mortality in an endemic situation, not influenced by outbreaks and consequently certain patients and C. difficile strains.
METHODS: Between 2006 and 2009, 13 Dutch hospitals included all hospitalized CDI patients. Nine hospitals individually matched each CDI patient to 2 control patients, based on ward and time of CDI hospitalization. Survival status was obtained via the Dutch Civil Registration System. Kaplan-Meier and Cox regression were used for survival analysis.
RESULTS: We identified 1366 patients with CDI (1.33 per 1000 admissions). All-cause mortality risk was 13% after 30 days and 37% after 1 year. The highest mortality was seen among elderly patients and patients with polymerase chain reaction ribotype 027. Three hundred seventeen CDI patients were matched to 317 patients without diarrhea and 232 patients with diarrhea, with a 30-day mortality risk of 5.4% and 8.6%, respectively. CDI patients had a 2.5-fold increased 30-day mortality rate compared to controls without diarrhea (hazard ratio 2.5 [95% confidence interval, 1.4-4.3]) when adjusted for age, sex, and underlying diseases. CDI-related death occurred mainly within 30 days after diagnosis.
CONCLUSIONS: Mortality among CDI patients is high, even in an endemic situation. Our results show that CDI is associated with to a 2.5-fold increase in 30-day mortality. This highlights the considerable disease burden and clinical impact of CDI, even in absence of an outbreak.

Entities:  

Mesh:

Year:  2013        PMID: 23300235     DOI: 10.1093/cid/cis1209

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  31 in total

1.  Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection.

Authors:  Marco Falcone; Alessandro Russo; Federica Iraci; Paolo Carfagna; Paola Goldoni; Vincenzo Vullo; Mario Venditti
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

2.  Treatment of Clostridioides difficile Infection and Non-compliance with Treatment Guidelines in Adults in 10 US Geographical Locations, 2013-2015.

Authors:  Shannon A Novosad; Yi Mu; Lisa G Winston; Helen Johnston; Elizabeth Basiliere; Danyel M Olson; Monica M Farley; Andrew Revis; Lucy Wilson; Rebecca Perlmutter; Stacy M Holzbauer; Tory Whitten; Erin C Phipps; Ghinwa K Dumyati; Zintars G Beldavs; Valerie L S Ocampo; Corinne M Davis; Marion Kainer; Dale N Gerding; Alice Y Guh
Journal:  J Gen Intern Med       Date:  2019-11-25       Impact factor: 5.128

3.  NAP1 strain type predicts outcomes from Clostridium difficile infection.

Authors:  Isaac See; Yi Mu; Jessica Cohen; Zintars G Beldavs; Lisa G Winston; Ghinwa Dumyati; Stacy Holzbauer; John Dunn; Monica M Farley; Carol Lyons; Helen Johnston; Erin Phipps; Rebecca Perlmutter; Lydia Anderson; Dale N Gerding; Fernanda C Lessa
Journal:  Clin Infect Dis       Date:  2014-03-05       Impact factor: 9.079

Review 4.  Management of adult Clostridium difficile digestive contaminations: a literature review.

Authors:  Fanny Mathias; Christophe Curti; Marc Montana; Charléric Bornet; Patrice Vanelle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-29       Impact factor: 3.267

5.  Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital.

Authors:  S M Heimann; J J Vehreschild; O A Cornely; H Wisplinghoff; M Hallek; R Goldbrunner; B W Böttiger; T Goeser; A Hölscher; S Baldus; F Müller; N Jazmati; S Wingen; B Franke; M J G T Vehreschild
Journal:  Infection       Date:  2015-06-30       Impact factor: 3.553

6.  Emphysematous cystitis due to recurrent Clostridium difficile infection.

Authors:  Michel E van Genderen; Jeroen G J Jonkman; Michiel van Rijn; Adriaan Dees
Journal:  BMJ Case Rep       Date:  2014-12-17

Review 7.  Epidemiology of Clostridium difficile infection.

Authors:  Daryl D Depestel; David M Aronoff
Journal:  J Pharm Pract       Date:  2013-10

8.  Preclinical studies of amixicile, a systemic therapeutic developed for treatment of Clostridium difficile infections that also shows efficacy against Helicobacter pylori.

Authors:  Paul S Hoffman; Alexandra M Bruce; Igor Olekhnovich; Cirle A Warren; Stacey L Burgess; Raquel Hontecillas; Monica Viladomiu; Josep Bassaganya-Riera; Richard L Guerrant; Timothy L Macdonald
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

9.  Fecal Transplants by Colonoscopy and Capsules Are Cost-Effective Strategies for Treating Recurrent Clostridioides difficile Infection.

Authors:  Yuying Luo; Aimee L Lucas; Ari M Grinspan
Journal:  Dig Dis Sci       Date:  2019-09-06       Impact factor: 3.199

10.  Epidemic Clostridium difficile strains demonstrate increased competitive fitness compared to nonepidemic isolates.

Authors:  Catherine D Robinson; Jennifer M Auchtung; James Collins; Robert A Britton
Journal:  Infect Immun       Date:  2014-04-14       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.